Tumor-Infiltrating Lymphocytes: Clinical Experience.

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has demonstrated significant efficacy in treating advanced, refractory metastatic melanoma.
• Objective response rates of approximately 50% have been consistently observed across multiple clinical centers.

Purpose of the Study:

• To summarize the clinical experience of TIL ACT in melanoma.
• To discuss advancements and future directions for improving TIL ACT.
• To present recent clinical findings of TIL ACT in nonmelanoma malignancies.

Main Methods:

• Utilizing lymphodepletion and high-dose interleukin 2 in conjunction with TIL ACT.
• Identifying and selecting tumor-specific T-cell populations for enhanced therapeutic targeting.
• Analyzing clinical outcomes in patients with metastatic melanoma and other cancers.

Main Results:

• TIL ACT provides durable responses, with complete regressions leading to long-term disease-free survival, suggesting potential for cure in melanoma patients.
• The therapy has proven valuable as salvage treatment for patients with extensive metastases who have failed prior therapies, including checkpoint inhibitors.
• Emerging data indicates the successful application of TIL ACT in nonmelanoma cancers.

Conclusions:

• TIL ACT is a highly effective treatment for advanced melanoma, offering durable responses and a potential cure.
• Ongoing research is focused on optimizing TIL ACT for broader application and improved outcomes.
• The expansion of TIL ACT to nonmelanoma malignancies represents a significant advancement in cancer immunotherapy.